PT1477187E - Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos - Google Patents

Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos Download PDF

Info

Publication number
PT1477187E
PT1477187E PT04019466T PT04019466T PT1477187E PT 1477187 E PT1477187 E PT 1477187E PT 04019466 T PT04019466 T PT 04019466T PT 04019466 T PT04019466 T PT 04019466T PT 1477187 E PT1477187 E PT 1477187E
Authority
PT
Portugal
Prior art keywords
implant
drugs
formulation
controlled release
hydrophobic agents
Prior art date
Application number
PT04019466T
Other languages
English (en)
Portuguese (pt)
Inventor
Vernon G Wong
Frank Kochinke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23823541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1477187(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT1477187E publication Critical patent/PT1477187E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
PT04019466T 1995-06-02 1996-05-31 Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos PT1477187E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/459,134 US5869079A (en) 1995-06-02 1995-06-02 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents

Publications (1)

Publication Number Publication Date
PT1477187E true PT1477187E (pt) 2011-09-01

Family

ID=23823541

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04019466T PT1477187E (pt) 1995-06-02 1996-05-31 Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos

Country Status (18)

Country Link
US (9) US5869079A (enExample)
EP (4) EP0831912B2 (enExample)
JP (3) JPH11506450A (enExample)
KR (1) KR19990022212A (enExample)
CN (1) CN1191492A (enExample)
AT (2) ATE315409T1 (enExample)
AU (1) AU721421B2 (enExample)
BR (1) BR9608642A (enExample)
CA (2) CA2222889C (enExample)
DE (1) DE69635734T3 (enExample)
DK (1) DK1477187T3 (enExample)
ES (2) ES2256859T5 (enExample)
MY (1) MY132179A (enExample)
PL (1) PL323747A1 (enExample)
PT (1) PT1477187E (enExample)
RU (1) RU2175561C2 (enExample)
TW (1) TW487580B (enExample)
WO (1) WO1996038174A1 (enExample)

Families Citing this family (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
EP0885014B1 (en) * 1996-03-05 2002-10-23 Robert Gurny Pharmaceutical compositions containing buffered ortho ester polymers
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
AU738338B2 (en) * 1997-08-11 2001-09-13 Allergan, Inc. Sterile bioerodible implant device with improved biocompatability and method
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7445792B2 (en) * 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
EP0985413A1 (de) * 1998-08-06 2000-03-15 Jörg Michael Dr. Dr. Schierholz Medizinprodukte mit retardierter pharmakologischer Aktivität und Verfahren zu ihrer Herstellung
DE59913045D1 (de) * 1998-08-06 2006-04-06 Schierholz Joerg Michael Medizinprodukte mit retardierter pharmakologischer aktivität und verfahren zu ihrer herstellung
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
FR2770134B1 (fr) * 1998-10-28 2002-06-07 Delab Formulations solides ou semi-solides pour administration locale
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
US6113638A (en) * 1999-02-26 2000-09-05 Williams; Lytton A. Method and apparatus for intervertebral implant anchorage
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010049422A1 (en) * 2000-04-14 2001-12-06 Phaneuf Matthew D. Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP3167872B1 (en) 2000-07-05 2020-10-14 Allergan, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2206298C2 (ru) * 2000-09-22 2003-06-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ лечения глаукомы
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
EP1550471A1 (en) * 2000-11-29 2005-07-06 Allergan Inc. Intraocular implants for preventing transplant rejection in the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
CA2432438C (en) * 2001-01-09 2011-04-26 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US7592016B2 (en) * 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
GB0116920D0 (en) * 2001-07-11 2001-09-05 Sulzer Vascutek Ltd Delivery system
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
PT1484054E (pt) * 2002-02-22 2012-11-28 Santen Pharmaceutical Co Ltd Sistema de administração de fármaco para administração subconjuntival de partículas finas
KR101173497B1 (ko) * 2002-03-11 2012-08-14 알콘, 인코퍼레이티드 이식 가능한 약물 전달 시스템
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
BR0310057A (pt) 2002-05-17 2007-04-10 Othera Pharmaceuticals Inc melhoria do desenvolvimento de catarata e outras doenças oftálmicas
JP2005527302A (ja) * 2002-05-24 2005-09-15 アンジオテック インターナショナル アーゲー 医療用移植物をコーティングするための組成物および方法
RU2207093C1 (ru) * 2002-05-28 2003-06-27 Государственное учреждение Тверская государственная медицинская академия Способ временного склерального пломбирования с применением эксплантатов из полигликолидного волокна
ES2301807T3 (es) * 2002-06-13 2008-07-01 Novartis Ag Compuestos de amoniociclodextrina cuaternizados.
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
PL206594B1 (pl) * 2002-07-15 2010-08-31 Alcon Kompozycja implantu śródocznego i zastosowanie leku oftalmicznego w połączeniu z niskocząsteczkowym związkiem lipofilowym do jej wytwarzania
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
CZ294328B6 (cs) * 2002-08-22 2004-11-10 Pliva-Lachema A. S. Biodegradabilní kompozice s prolongovaným uvolňováním biologicky aktivní látky a způsob její výroby
BR0314013A (pt) * 2002-09-06 2005-07-12 Abbott Lab Equipamento médico contendo inibidor de hidratação
JP2006507368A (ja) * 2002-09-29 2006-03-02 サーモディックス，インコーポレイティド ステロイド含有治療剤の網膜下投与方法；脈絡膜及び網膜に薬力学作用を局在化するための方法；並びに網膜疾患の治療及び／又は予防のための関連する方法
US20040221855A1 (en) * 2002-10-17 2004-11-11 Paul Ashton Methods for monitoring treatment of disease
WO2004034975A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
KR20050085367A (ko) * 2002-12-04 2005-08-29 산텐 세이야꾸 가부시키가이샤 결막하 데포에 의한 약물 송달 시스템
JP2004196787A (ja) * 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
WO2004071398A2 (en) * 2003-02-17 2004-08-26 Cipla Ltd Pharmaceutical patch
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8012115B2 (en) * 2003-02-18 2011-09-06 S.K. Pharmaceuticals, Inc. Optic nerve implants
RU2005129278A (ru) * 2003-02-20 2006-01-27 Алькон, Инк. (Ch) Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз
MXPA05008561A (es) * 2003-02-20 2005-11-04 Alcon Inc Uso de esteroides para tratar personas que sufren de trastornos oculares.
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
WO2004112772A1 (en) * 2003-06-13 2004-12-29 Alcon, Inc. Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
RU2248777C1 (ru) * 2003-06-18 2005-03-27 Государственное учреждение Межотраслевой научно-технический комлекс "Микрохирургия глаза" им. акад. С.Н. Федорова Способ доставки лекарственных веществ к заднему отрезку глазного яблока при интравитреальных вмешательствах по поводу отслойки сетчатки, осложненной пролиферативной витреоретинопатией
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US20100158880A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Regeneration and repair of neural tissue following injury
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
AU2004252568B2 (en) 2003-06-27 2011-06-30 Ethicon, Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
TWI347847B (en) * 2003-08-20 2011-09-01 Santen Pharmaceutical Co Ltd Drug delivery system for sub-tenon administration of fine particles
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
RU2336074C2 (ru) * 2003-11-12 2008-10-20 Аллерган, Инк. Композиции и способы лечения заднего сегмента глаза
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CN100558360C (zh) 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
WO2005061003A1 (en) * 2003-12-12 2005-07-07 Medtronic, Inc. Anti-infective medical device
US8691258B2 (en) * 2003-12-12 2014-04-08 Medtronic, Inc. Anti-infective medical device
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
AU2011213904B2 (en) * 2004-04-30 2014-06-05 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
AU2005247480A1 (en) * 2004-05-25 2005-12-08 Qlt Inc. Oculoselective drugs and prodrugs
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
US20060009498A1 (en) 2004-07-12 2006-01-12 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
AU2013221985B2 (en) * 2004-07-12 2016-09-01 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Operations Gmbh Methods for manufacturing delivery devices and devices thereof
US20060116404A1 (en) 2004-09-24 2006-06-01 Gary Robinson CAI-based systems and methods for the localized treatment of ocular and other diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060068012A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP1793803B1 (en) * 2004-10-01 2012-11-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
RU2007125978A (ru) * 2004-12-10 2009-01-20 Талима Терапьютикс, Инк. (Us) Композиции и способы для лечения заболеваний ногтей
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060166361A1 (en) * 2004-12-21 2006-07-27 Agnieszka Seyda Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
JP5425400B2 (ja) 2004-12-23 2014-02-26 エシコン・インコーポレイテッド 産褥由来細胞を用いた脳卒中および他の急性神経変性障害の治療
PL1831356T3 (pl) 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Komórki poporodowe pochodzące z tkanki pępowinowej i sposoby ich wytwarzania i stosowania
US20060165810A1 (en) * 2004-12-28 2006-07-27 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
WO2007037849A2 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
AU2006299645B2 (en) 2005-09-30 2011-02-03 Io Therapeutics, Llc Treatment of cancer with specific RXR agonists
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
EP1937210B1 (en) 2005-10-18 2017-05-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
JP5180834B2 (ja) 2005-11-29 2013-04-10 スミスクライン ビーチャム コーポレーション 治療方法
US9175261B2 (en) * 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
ES2391034T3 (es) * 2005-12-19 2012-11-20 Ethicon, Inc. Expansión in vitro de células derivadas postparto en frascos rotatorios
SG170789A1 (en) * 2005-12-28 2011-05-30 Ethicon Inc Treatment of peripheral vascular disease using postpartum-derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP1993584B1 (en) 2006-02-02 2012-05-30 Allergan, Inc. Inhibitors of CXCR4 activity for use in the treatment of ocular disorders
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
ES2717607T3 (es) 2006-03-31 2019-06-24 Mati Therapeutics Inc Estructuras de administración de fármacos y composiciones para el sistema nasolagrimal
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
US20080089923A1 (en) * 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
JP5419699B2 (ja) 2006-10-31 2014-02-19 エボニック コーポレイション 球状化されたポリマー粒子
US8586556B2 (en) * 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CA2670990A1 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
CN103497148B (zh) 2007-02-22 2016-06-01 科尔比制药公司 羟胺化合物及其用法
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
CA2704111C (en) * 2007-05-14 2017-06-20 Sustained Nano Systems Llc Hypercompressed particles for controlled release of ophthalmic medications
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US8329220B2 (en) * 2007-08-24 2012-12-11 Aegis Therapeutics, Llc Controlled release formulations
WO2009046299A2 (en) * 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
BRPI0818183A2 (pt) * 2007-10-05 2019-07-16 Ethicon Inc reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
RU2431469C1 (ru) * 2008-03-03 2011-10-20 Аллерган, Инк. Композиции кеторолака трометамина для лечения или профилактики глазной боли
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US8283350B2 (en) 2008-08-01 2012-10-09 Alpha Synergy Development, Inc. Compositions and methods for reducing capillary permeability
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
EP2346515A4 (en) * 2008-09-25 2013-01-23 Invivo Therapeutics Corp SPINAL CORD INJURY, INFLAMMATION AND IMMUNE DISEASE: CONTROLLED LOCAL RELEASE OF THERAPEUTIC AGENTS
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
WO2010071864A1 (en) 2008-12-19 2010-06-24 Ethicon, Incorporated Treatment of lung and pulmonary diseases and disorders
WO2010071862A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2010111663A1 (en) 2009-03-26 2010-09-30 Ethicon, Inc. Human umbilical cord tissue cells as therapy for alzheimer' s disease
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2979355C (en) 2009-05-18 2023-02-21 Dose Medical Corporation Drug eluting ocular implant
MX338355B (es) * 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
EP2442812A1 (en) 2009-06-19 2012-04-25 Altos Vision Limited Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
CN106139123A (zh) * 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US20120219543A1 (en) 2009-10-20 2012-08-30 Raphael Scharfmann Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
WO2011075481A1 (en) 2009-12-16 2011-06-23 Allergan, Inc. Intracameral devices for sustained delivery
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CA2789895C (en) 2010-03-08 2019-04-09 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer
CA2798145C (en) 2010-05-04 2022-10-18 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
WO2011159824A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. Composition and method for treating overactive bladder
US8993626B2 (en) 2010-06-25 2015-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treatment using sterculic acid
EP2595602B1 (en) 2010-07-21 2018-05-23 Allergan, Inc. SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
WO2012024072A1 (en) 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
EP2661269A1 (en) 2011-01-03 2013-11-13 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
WO2012112757A2 (en) 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2714016A1 (en) 2011-06-03 2014-04-09 Allergan, Inc. Targeted delivery of retinoid compounds to the sebaceous glands
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2720539B1 (en) 2011-06-14 2018-10-24 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CN103889434B (zh) 2011-06-21 2017-02-15 Bvw控股公司 含有乳香酸的医疗装置
EP2734261B1 (en) 2011-07-18 2018-02-21 Mor-Research Applications Ltd. A device for adjusting the intraocular pressure
EP2768307B1 (en) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10040749B2 (en) 2011-12-01 2018-08-07 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
CN109200013A (zh) 2011-12-05 2019-01-15 因赛普特有限责任公司 医用有机凝胶方法和组合物
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US9611513B2 (en) 2011-12-23 2017-04-04 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue derived cells
CN104204099A (zh) * 2012-01-13 2014-12-10 密苏里大学管委会 抗生物膜形成的低温等离子体涂层
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
ES2734554T3 (es) 2012-09-26 2019-12-10 Tangent Reprofiling Ltd Combinación de benzo(iso)oxazolpiperidinas con ácido linoleico conjugado
WO2014052518A1 (en) * 2012-09-27 2014-04-03 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
EP3530268B1 (en) 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutic treatment
AU2013336683A1 (en) 2012-10-24 2015-05-14 Biocopea Limited Drug combinations containing statins for treating cardiovascular diseases
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
BR112015014969B1 (pt) 2012-12-21 2021-12-07 Corium, Inc Aparelho de microestruturas e método de fabricar um aparelho de microestruturas
EP2943193A2 (en) 2013-01-14 2015-11-18 Health Clinics Limited Cancer drug and uses
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
JP6511401B2 (ja) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続型薬物送達インプラント
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
US9890127B2 (en) 2013-03-11 2018-02-13 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
EP4094799A1 (en) 2013-03-12 2022-11-30 Corium, Inc. Microprojection applicators
EP2967824B1 (en) 2013-03-12 2020-11-04 Carnegie Mellon University Coated vaso-occlusive device for treatment of aneurysms
BR112015022025A8 (pt) 2013-03-14 2019-12-10 Hallux Inc composição e uso de um agente ativo
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2014151654A1 (en) * 2013-03-15 2014-09-25 Corium International, Inc. Microarray for delivery of therapeutic agent and methods of use
WO2014151769A1 (en) 2013-03-15 2014-09-25 Allergan, Inc. Compositions including encapsulated isotretinoin and methods for use thereof
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
EP3427661B1 (en) 2013-08-21 2020-05-13 Senseonics, Incorporated Drug elution for in vivo protection of bio-sensing analytes
JP6543431B2 (ja) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 眼内薬物送達デバイスおよび付随する方法
US20150209342A1 (en) 2014-01-28 2015-07-30 Allergan, Inc. Topical retinoid formulations, processes for making and methods of use
HRP20220759T1 (hr) 2014-02-11 2022-09-02 Mitokinin, Inc. Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
BR112016024102A2 (pt) 2014-04-17 2017-08-15 Seed Co Ltd dispositivo médico contendo droga aniônica
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
US20160008376A1 (en) 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
EP3188714A1 (en) 2014-09-04 2017-07-12 Corium International, Inc. Microstructure array, methods of making, and methods of use
HK1249460A1 (zh) 2015-03-06 2018-11-02 Aerie Pharmaceuticals, Inc. 植入物施用器和植入物的施用方法
WO2017004067A1 (en) 2015-06-29 2017-01-05 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
JP6914931B2 (ja) 2015-07-23 2021-08-04 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用
WO2017020001A2 (en) 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
JP2018523673A (ja) 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体
JP6898310B2 (ja) 2015-09-02 2021-07-07 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． ６員アザヘテロ環を含有するデルタ−オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
HK1259307A1 (zh) 2015-10-07 2019-11-29 阿佩利斯制药有限公司 给药方案
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US12048761B2 (en) * 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US20190125669A1 (en) * 2016-04-17 2019-05-02 Children's Medical Center Corporation Systems and methods for steroidal gels
CN115120405A (zh) 2016-04-20 2022-09-30 多斯医学公司 生物可吸收眼部药物的递送装置
KR20190026758A (ko) 2016-07-05 2019-03-13 얀센 바이오테크 인코포레이티드 전구 세포를 사용한 망막 혈관 질병의 치료
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
EP3541408B1 (en) 2016-11-15 2024-11-13 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
US11702408B2 (en) 2017-02-17 2023-07-18 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
AU2018221705B2 (en) 2017-02-17 2022-10-27 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
AU2018249627B2 (en) 2017-04-07 2025-04-03 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
KR102872720B1 (ko) 2017-05-05 2025-10-16 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 기질 결합 소낭의 안구에의 적용
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
KR20200019228A (ko) 2017-06-21 2020-02-21 미토키닌, 인크. 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
AU2018314280B2 (en) 2017-08-11 2023-07-20 Rsem, Société En Commandite Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
US12201315B2 (en) 2017-10-16 2025-01-21 Retriever Medical, Inc. Clot removal methods and devices with multiple independently controllable elements
US20190110804A1 (en) 2017-10-16 2019-04-18 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
CA3195810A1 (en) 2017-10-16 2022-04-21 Michael Bruce Horowitz Clot removal methods and devices with multiple independently controllable elements
JP7416700B2 (ja) 2017-11-14 2024-01-17 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
MA51162A (fr) 2017-12-15 2020-10-21 Apellis Pharmaceuticals Inc Schémas posologiques et compositions et procédés associés
CA3091810A1 (en) 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
EP3787609A4 (en) * 2018-05-01 2022-01-05 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
CA3097927A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
JP7394850B2 (ja) 2018-11-02 2023-12-08 センセオニクス，インコーポレーテッド 分析物指示薬上の薬剤溶出マトリクス
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof
MX2022007056A (es) * 2019-12-10 2022-07-11 Alcon Inc Insertos oculares polimericos disolvibles con un polimero biodegradable.
AU2021208631A1 (en) 2020-01-17 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of CRX-autosomal dominant retinopathies
WO2021173929A1 (en) 2020-02-26 2021-09-02 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
EP4157309A1 (en) 2020-06-01 2023-04-05 Black Cat Bio Limited Compositions and methods for treating infections and netopathy
GB202018889D0 (en) * 2020-12-01 2021-01-13 UCB Biopharma SRL Formulations
EP4444269A1 (en) 2021-12-06 2024-10-16 Breye Therapeutics ApS Danegaptide formulation for applicatoin in the eye
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
MX2024006980A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr en el tratamiento de cáncer her2+ resistente a fármacos.
US11779553B1 (en) * 2022-11-28 2023-10-10 Atif B. D. Collins Methods and devices for treatment of eyelid ptosis
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636865A (enExample) * 1962-08-31
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
SE390255B (sv) * 1974-02-18 1976-12-13 N G Y Torphammar Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4402979A (en) * 1980-03-21 1983-09-06 Merck & Co., Inc. & Laboratories Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
IN156886B (enExample) * 1981-08-22 1985-11-30 Council Scient Ind Res
JPS58126435U (ja) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4451254A (en) * 1982-03-15 1984-05-29 Eli Lilly And Company Implant system
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US4640941A (en) * 1985-11-25 1987-02-03 Alcon Laboratories Hydrogels containing siloxane comonomers
EP0265457A4 (en) * 1986-04-10 1989-07-26 Daratech Pty Ltd VACCINE AND IMPLANT.
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4821210A (en) * 1987-04-02 1989-04-11 General Electric Co. Fast display of three-dimensional images
EP0391909B1 (en) * 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
SG49267A1 (en) * 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5268178A (en) * 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
ATE102022T1 (de) † 1990-08-30 1994-03-15 Senju Pharma Co Zusammensetzung zur kontrollierten abgabe von medikamenten.
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5153002A (en) * 1991-03-04 1992-10-06 University Of Montreal Biocompatible gradient controlled release implant
US5597897A (en) * 1991-06-21 1997-01-28 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US6045791A (en) * 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5618563A (en) * 1992-09-10 1997-04-08 Children's Medical Center Corporation Biodegradable polymer matrices for sustained delivery of local anesthetic agents
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5314419A (en) * 1992-10-30 1994-05-24 Pelling George E Method for dispensing ophthalmic drugs to the eye
EP0669127B1 (en) * 1992-11-18 1999-08-11 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5393765A (en) † 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (de) * 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraokulare Linsenanordnung zur Astigmatismuskorrektur
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5755785A (en) * 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
CA2149164C (en) * 1995-05-11 2009-03-03 Zlatko Korunic Diatomaceous earth insecticidal composition
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5693335A (en) * 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5941250A (en) * 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
ATE246489T1 (de) * 1997-03-31 2003-08-15 Alza Corp Implantierbares diffusionabgabesystem
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
AU738338B2 (en) * 1997-08-11 2001-09-13 Allergan, Inc. Sterile bioerodible implant device with improved biocompatability and method
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
JP3937533B2 (ja) * 1997-11-07 2007-06-27 セイコーエプソン株式会社 遠隔座標入力装置および遠隔座標入力方法
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
WO2000030532A1 (en) * 1998-11-20 2000-06-02 University Of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7335803B2 (en) * 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6534542B2 (en) * 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7386835B1 (en) * 2002-03-22 2008-06-10 Emc Corporation Technique for graphical user interface modification
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20040048099A1 (en) * 2002-08-29 2004-03-11 Chen Jian Ping Organic light-emitting device using iptycene derivatives
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20060009498A1 (en) * 2004-07-12 2006-01-12 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
US7357394B2 (en) * 2004-10-01 2008-04-15 Sri Acquisition Corp. Modular shooting range
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods

Also Published As

Publication number Publication date
CA2762921A1 (en) 1996-12-05
MX9709218A (es) 1998-06-30
US20060204543A1 (en) 2006-09-14
US5869079A (en) 1999-02-09
EP0831912A4 (en) 2000-08-30
CA2222889A1 (en) 1996-12-05
ES2256859T3 (es) 2006-07-16
PL323747A1 (en) 1998-04-14
EP1637164A3 (en) 2007-09-05
US20080124377A1 (en) 2008-05-29
EP1477187A1 (en) 2004-11-17
AU721421B2 (en) 2000-07-06
US20030095995A1 (en) 2003-05-22
US20060067966A1 (en) 2006-03-30
WO1996038174A1 (en) 1996-12-05
DE69635734T2 (de) 2006-07-13
JP2011005300A (ja) 2011-01-13
DE69635734D1 (de) 2006-04-06
ATE516049T1 (de) 2011-07-15
MY132179A (en) 2007-09-28
ES2256859T5 (es) 2009-04-01
TW487580B (en) 2002-05-21
EP0831912A1 (en) 1998-04-01
DE69635734T3 (de) 2009-04-23
EP0831912B2 (en) 2008-10-29
EP0831912B1 (en) 2006-01-11
EP1477187B1 (en) 2011-07-13
US20090148499A1 (en) 2009-06-11
EP1637164A2 (en) 2006-03-22
US20050048098A1 (en) 2005-03-03
KR19990022212A (ko) 1999-03-25
RU2175561C2 (ru) 2001-11-10
EP2298353A1 (en) 2011-03-23
JPH11506450A (ja) 1999-06-08
AU5962496A (en) 1996-12-18
CN1191492A (zh) 1998-08-26
BR9608642A (pt) 1999-08-24
ES2368951T9 (es) 2012-04-09
ES2368951T3 (es) 2011-11-23
US20050191334A1 (en) 2005-09-01
US7048946B1 (en) 2006-05-23
JP2006192282A (ja) 2006-07-27
CA2222889C (en) 2012-01-03
EP1477187B9 (en) 2012-02-22
ATE315409T1 (de) 2006-02-15
DK1477187T3 (da) 2011-10-31

Similar Documents

Publication Publication Date Title
PT1477187E (pt) Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos
RU98100252A (ru) Усовершенствованный состав для регулируемого выделения лекарственных средств посредством комбинирования гидрофильных и гидрофобных агентов
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
AU2223095A (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
DE69324466D1 (de) L-dopa Ester-enthaltende Zusammensetzung
IL207613A0 (en) Controlled release hydrocodone formulations
CA2235919A1 (en) Non-polymeric sustained release delivery system
FR2811571B1 (fr) Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
PL323832A1 (en) Composition for prolonged release of human growth hormone
EP0643963A3 (en) Biologically erodible device for the administration of active substances.
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
JPH09506331A (ja) 乾癬処置の治療システム
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
EP0987022A4 (en) PREVENTIVE AND HEALING MEDICINES FOR ULCERATIVE KOLITIS AND / OR MORBUS CROHN